Cure Mapt Ftd
Nonprofit profile at a glance
- EIN
- 932513996
- IRS 990 coverage
- 2025–2025
- Forms available
- Form 990 2025, Form 990-N 2023
- Location
- Denver, CO, USA
- Phone
- 7204321352
- Rating
- 66
- Verdict
- SUPPORTED
- Rating confidence
- Moderate
- Sector
- Alliance/Advocacy Organizations
Reported finances
- Revenue
- $44,297
- Expenses
- $30,751
- Assets
- $15,927
- Liabilities
- $0
Source: IRS Form 990. Selected filing: tax year 2025. Amounts in USD.
Leadership & pay
5 people listed
People named in this filing
- Barbara Frommell (Chair)
- Barbara Dawson (Vice Chair)
- David Frommell (Secretary)
Selected names, not a complete roster or a statement of current roles. Open leadership details for the complete filed list.
Source: IRS Form 990. Selected filing: tax year 2025. Names and roles reflect this filing, not necessarily current officeholders.
Overview
Mission
Cure MAPT FTD increases awareness of the brain disease commonly known as frontotemporal dementia (FTD), of the importance of genetic testing, and specifically of the disease caused by a mutation of the MAPT (microtubule-associated protein tau) gene. Through regular meetings with our volunteer Scientific Advisory Board and active members, we ensure open communication, strong advocacy, and unwavering support for the MAPT community in an effort to find a cure. We actively participate in medical and scientific conferences that are focused on the genetics of FTD and dementia-related issues. Cure MAPT FTD advocates for MAPT-specific trials and access to other FTD gene-specific trials. Currently there are no interventional, drug or gene therapy trials that are available for MAPT patients, regardless of symptom status. We actively participate in key scientific conferences worldwide, building vital connections with researchers and fostering collaboration.
What it reported doing in 2025
We participated in a FDA Patient Listening Session in May 2025 which gave MAPT FTD persons and caregivers a direct platform to share their lived experiences with federal regulators and the research community. We advocated at the session, as well as at conferences, and throughout the year with the global scientific and pharma community, for MAPT-specific trials and access to other FTD gene-and tau-specific trials. To accelerate this progress, we've launched a global survey and HIPPA compliant database of individuals with MAPT mutations, making it easier for scientists to identify potential participants for clinical trials.
Operating model
- Revenue model
- Donor-supported. 100% of the money available for current operations came from contributions and gifts.
- Distribution model
- Direct operator. The filing allocates 100% of reported program-service expenses outside its grant, affiliate-payment, and member-benefit lines. This expense classification does not rule out separately announced grant awards.
The verdict
SUPPORTED - The filed numbers largely add up and most voting board members are independent. A relatively small share of available resources goes toward mission work and some filing-based governance responses are negative or unanswered.
Rating breakdown
- Financial Efficiency: 53
- Transparency & Controls: 90
- Accountability: 76
- Sustainability: 57
- Growth: NotEnoughData
Detailed rating inputs
Financial Efficiency
- Mission deployment rate: 50.9%; rating input score 51
- Program expense ratio: 73.4%; rating input score 73
- Fundraising efficiency: Limited
Transparency & Controls
- Consistency checks: 100%; rating input score 100; 63rd percentile among comparable filings
- Pay-setting controls: Limited
- Foreign activity oversight: Limited
- Grant itemization coverage: Limited
- Major donor itemization: Limited
- Related-party transparency: Limited
Accountability
- Independent voting board: 100%; rating input score 100; 64th percentile among comparable filings
- Governance controls: 3 of 7 controls in place; rating input score 43
- Conflict-of-interest policy: Pass
- Whistleblower policy: Fail
- Document-retention policy: Fail
- CEO compensation review process: NotApplicable
- Other executive compensation review process: NotApplicable
- Form 990 shared with the board: Pass
- Board meeting minutes documented: Pass
- Audit committee oversight: Missing
- Independent financial-statement audit: Fail
Sustainability
- Operating margin: 30.6%; rating input score 77; 77th percentile among comparable filings
- Total-asset coverage ratio: 0.52; rating input score 20; 20th percentile among comparable filings
- Liabilities to assets ratio: 0; rating input score 66; 66th percentile among comparable filings
- Officer compensation ratio: 0%; rating input score 58; 58th percentile among comparable filings
Growth
- Program expense growth: Limited
- Revenue growth: Limited
- Asset growth: Limited
Details
- Where the money goes: 50.9% of revenue deployed · 73.4% of spending went to programs
- Governance: 5 of 5 board members independent · 3 of 7 filing controls reported
- Programs: 3 filed program accomplishments · $23K in reported program spending
- Leadership: top reported pay $0 · 5 people listed
- Consistency: 40 of 40 current checks pass
- Schedules: 3 filed schedules
- Contacts: How to reach this organization
- Grant readiness: Federal tax and exclusion status, award history, and grant-maker relationships.
- People: Everyone the filings name, and which of them the filings identify by more than a name.
Key Signals
Signals prioritize questions for review. They are not findings of misconduct.
- Review — Financial Efficiency: Mission deployment rate scored 51/100.
- Moderate — Accountability: Governance controls: 3 of 6 not reported.
- High — Sustainability: Total-asset coverage ratio scored 20/100.
- Review — Sustainability: Officer compensation ratio scored 58/100.